SEARCH

SEARCH BY CITATION

References

  • 1
    Yang CW, Kim YO, Kim YS et al. Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV sero-positive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay. Am J Nephrol 1998; 18: 373378.
  • 2
    Toupance O, Bouedjoro-Camus MC, Carquin J et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: A cohort study with case-control analyses. Transpl Int 2000; 13: 413419.
  • 3
    Hokeberg I, Eriksson BM, Zweygberg-Wirgart B, Tufvesson G, Olding-Stenkvist E, Grillner L. Diagnostic markers and risk factors of cytomegalovirus infection and disease in renal allograft recipients. Scand J Infect Dis 1995; 27: 435440.
  • 4
    Sagedal S, Nordal KP, Hartmann A et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000; 70: 11661174.
  • 5
    Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990; 12(Suppl 7): S754S766.
  • 6
    Sagedal S, Nordal KP, Hartmann A et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850856.
  • 7
    Sagedal S, Hartmann A, Nordal KP et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329337.
  • 8
    Green M, Avery RK, Preiksaitis J et al. Guidelines for the prevention and management of infectious complications of solid organ transplantation. Am J Transplant 2004; 4(Suppl 10): 5158.
  • 9
    Hart GD, Paya CV. Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 7381.
  • 10
    Schnitzler MA, Lowell JA, Hmiel SP et al. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: The importance of HLA-DR matching. J Am Soc Nephrol 2003; 14: 780785.
  • 11
    Bock GH, Sullivan EK, Miller D et al. Cytomegalovirus infections following renal transplantation–effects on antiviral prophylaxis: A report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1997; 11: 665671.
  • 12
    Opelz G, Döhler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 928936.
  • 13
    Humar A, Michaels M, AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262274.
  • 14
    EBPG (European Expert Group on Renal Transplantation), European Renal Association (ERA-EDTA), European Society for Organ Transplantation (ESOT). European best practice guidelines for renal transplantation (part 1). Nephrol Dial Transplant 2000; 15(Suppl 7): 185.
  • 15
    Emery VC. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 8386.
  • 16
    Singh N. Cytomegalovirus infection in solid organ transplant recipients: New challenges and their implications for preventive strategies. J Clin Virol 2006; 35: 474477.
  • 17
    Einsele H, Reusser P, Bornhauser M et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 2006; 107: 30023008.
  • 18
    Pescovitz MD. Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation 2006; 82(2 Suppl): S4S8.
  • 19
    Pellegrin I, Garrigue I, Binquet C et al. Evaluation of new quantitative assays for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency virus-positive patients. J Clin Microbiol 1999; 37: 31243132.
  • 20
    Von Muller L, Hampl W, Hinz J et al. High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assay. J Clin Microbiol 2002; 40: 22852287.
  • 21
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457481.
  • 22
    Birk PE, Chavers BM. Does cytomegalovirus cause glomerular injury in renal allograft recipients? J Am Soc Nephrol 1997; 8: 18011808.
  • 23
    Boyce NW, Hayes K, Gee D et al. Cytomegalovirus infection complicating renal transplantation and its relationship to acute transplant glomerulopathy. Transplantation 1988; 45: 706709.
  • 24
    Soderberg-Naucler C, Emery VC. Viral infections and their impact on chronic renal allograft dysfunction. Transplantation 2001; 71(11 Suppl): SS24SS30.
  • 25
    Weissinger EM, Wittke S, Kaiser T et al. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int 2004; 65: 24262434.
  • 26
    Haubitz M, Wittke S, Weissinger EM et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 2005; 67: 23132320.
  • 27
    Wittke S, Mischak H, Walden M, Kolch W, Radler T, Wiedemann K. Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: Towards new diagnostic and therapeutic approaches. Electrophoresis 2005; 26: 14761487.
  • 28
    Mischak H, Apweiler R, Banks RE et al. Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl 2007; 1: 148156.
  • 29
    Kliem V, Fricke L, Wollbrink T et al. In comparison to preemptive therapy general CMV prophylaxis with ganciclovir improves transplant survival significantly following renal transplantation [abstract]. Transplantationsmedizin 2006; 18(Suppl 2): 127.
  • 30
    Strom TB. Rejection–more than the eye can see. N Engl J Med 2005; 353: 23942396.
  • 31
    Muthukumar T, Dadhania D, Ding R et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353: 23422351.
  • 32
    Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870880.
  • 33
    Strippoli GF, Hodson EM, Jones CJ, Craig JC. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database of Syst Rev 2006; 1: CD005133.
  • 34
    Hodson EM, Jones CA, Webster AC et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365: 21052115.
  • 35
    Lowance D, Neumayer HH, Legendre CM et al for the International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999; 340: 14621470.
  • 36
    Khoury JA, Storch GA, Bohl DL et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 21342143.
  • 37
    Fishman JA, Emery V, Freeman R et al. Cytomegalovirus in transplantation–challenging the status quo. Clin Transplant 2007; 21: 149158.
  • 38
    Freeman RB, Paya C, Pescovitz MD et al. Valganciclovir Solid Organ Transplant Study Group. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004; 78: 17651773.